Section Arrow
Quote
MGX.NASDAQ
- Metagenomi Therapeutics Inc.
Quotes are at least 15-min delayed:2026/03/05 06:01 EST
Pre Market
Last
 --
-- (--)
Bid
1.6
Ask
1.8
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 1.6
+0.09 (+5.96%)
Day High 
1.63 
Prev. Close
1.51 
1-M High
1.615 
Volume 
165.98K 
Bid
1.6
Ask
1.8
Day Low
1.5199 
Open
1.52 
1-M Low
1.39 
Market Cap 
56.70M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.51 
20-SMA 1.5 
50-SMA 1.61 
52-W High 3.95 
52-W Low 1.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.39/-2.60
Enterprise Value
96.88M
Balance Sheet
Book Value Per Share
4.75
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
52.30M
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
KLTOKlotho Neurosciences Inc0.4126-0.1304-24.01%-- 
Pre Market 0.4119 -0.0007 -0.17%
IBOImpact BioMedical Inc.0.4133+0.0033+0.80%-- 
Pre Market 0.7493 +0.336 +81.30%
CANFCan-Fite Biopharma Ltd6.02+1.02+20.40%-- 
Pre Market 5.43 -0.59 -9.80%
IBRXImmunityBio9-1.005-10.04%-- 
Pre Market 8.98 -0.02 -0.22%
QNCXQuince Therapeutics0.104+0.007+7.22%-- 
Pre Market 0.1206 +0.0166 +15.96%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Metagenomi Therapeutics Inc formerly, Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A, Refractory Hypertension, Cardiovascular diseases, and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.